Molecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge model

Vaccine

Volumn 33, Issue 35, 2015, Pages 4313-4320

  Villarreal, Daniel O ^a   Svoronos, Nikolaos ^a,b   Wise, Megan C ^a   Shedlock, Devon J ^a   Morrow, Matthew P ^c   Conejo Garcia, Jose R ^b   Weiner, David B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

^c Inovio Pharmaceuticals   (United States)

Author keywords

Adjuvants; CD8 T cells; DNA vaccines; HIV; IL 33; LCMV

Indexed keywords

CD8 ANTIGEN; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 33; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; DRUG POTENTIATION; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNOGENICITY; IN VIVO STUDY; LD50; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLEEN CELL; SURVIVAL RATE; ANIMAL; ARENAVIRIDAE INFECTIONS; C57BL MOUSE; DISEASE MODEL; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; PATHOGENICITY;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; ARENAVIRIDAE INFECTIONS; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; IMMUNITY, CELLULAR; IMMUNOLOGIC MEMORY; INTERLEUKIN-33; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MICE, INBRED C57BL; VACCINES, DNA;

EID: 84939565785     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.03.086     Document Type: Article

References (34)

1. Gilbert S.C. T-cell-inducing vaccines-what's the future. Immunology 2012, 135(1):19-26.
2. Schijns V.E., Lavelle E.C. Trends in vaccine adjuvants. Expert Rev Vaccines 2011, 10(4):539-550.
3. Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33(4):492-503.
4. Bonilla W.V., Frohlich A., Senn K., Kallert S., et al. The alarmin interleukin-33 drives protective antiviral CD8(+) T cell responses. Science 2012, 335(6071):984-989.
5. Villarreal D.O., Wise M.C., Walters J.N., et al. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res 2014, 74(6):1789-1800.
6. Villarreal D.O., Weiner D.B. Interleukin-33: a switch-hitting cytokine. Curr Opin Immunol 2014, 28C:102-106.
7. Liew F.Y., Pitman N.I., McInnes I.B. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010, 10(2):103-110.
8. Klavinskis L.S., Whitton J.L., Oldstone M.B. Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection. J Virol 1989, 63(10):4311-4316.
9. Klavinskis L.S., Whitton J.L., Joly E., Oldstone M.B. Vaccination and protection from a lethal viral infection: identification, incorporation, and use of a cytotoxic T lymphocyte glycoprotein epitope. Virology 1990, 178(2):393-400.
10. Zhou X., Ramachaundran S., Mann M., Popkin D.L. Role of lymphocytic choriomeningitis virus (LCMV) in understanding viral immunology: past. Present Future Viruses 2012, 4(11):2650-2669.
11. Shedlock D.J., Talbott K.T., Cress C., Ferraro B., Tuyishme S., et al. A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge. Vaccine 2011, 29(39):6755-6762.
12. Yokoyama M., Zhang J., Whitton J.L. DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection. J Virol 1995, 69(4):2684-2688.
13. Shin H., Blackburn S.D., Blattman J.N., Wherry E.J. Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection. J Exp Med 2007, 204(4):941-949.
14. Pulendran B., Ahmed R. Immunological mechanisms of vaccination. Nat Immunol 2011, 12(6):509-517.
15. Olson J.A., McDonald-Hyman C., Jameson Sc, Hamilton S.E. Effector-like CD8(+) T cells in the memory population mediate potent protective immunity. Immunity 2013, 38(6):1250-1260.
16. Bachmann M.F., Wolint P., Schwarz K., Oxenius A. Recall proliferation potential of memory CD8+ T cells and antiviral protection. J Immunol 2005, 175(7):4677-4685.
17. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008, 8(6):247-258.
18. Wherry E.J., Teichgraber V., Becker T.C., Masopust D., Kaech S.M., et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003, 4(3):225-234.
19. Kaech S.M., Cui W. Transcriptional control of effector and memory CD8 T cell differentiation. Nat Rev Immunol 2012, 12(11):749-761.
20. Yang Q., Li G., Zhu Y., Liu L., Chen E., Turnquist H., et al. IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells. Eur J Immunol 2011, 41(11):3351-3360.
21. Ye F., Turner J., Flano E. Contribution of pulmonary KLRG1(high) and KLRG1(low) CD8 T cells to effector and memory responses during influenza virus infection. J Immunol 2012, 189(11):5206-5211.
22. Seder R.A., Ahmed R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol 2003, 4(9):835-842.
23. Joshi N.S., Cui W., Chandele A., Lee H.K., Urso D.R., Hagman J., et al. Inflammation directs memory precursor and short-lived effector CD8 T cells fates via the graded expression of T-bet transcription factor. Immunity 2007, 27(2):281-295.
24. Lighvani A.A., Frucht D.M., Jankovic D., Yamane H., et al. T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc Natl Acad Sci USA 2001, 98(26):15137-15142.
25. Yan J., Corbitt N., Pankhong P., Shin T., Khan A., Sardesai N.Y., et al. Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine. Vaccine 2011, 29(41):7173-7181.
26. Obeng-Adjei N., Choo D.K., Weiner D.B. Hydrodynamic immunization leads to poor CD8 T cell expansion, low frequency of memory CTLs and ineffective antiviral protection. Cancer Gene Ther 2013, 20:552-563.
27. Shedlock D.J., Aviles J., Talbott K.T., Wong G., Wu S.J., Villarreal D.O., et al. Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. Mol Ther 2013, 21:1432.
28. Wherry E.J., Blattman J.N., Murali-Krishna K., van der Most R., Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distrubution and results in distinct stages of functional impairment. J Virol 2003, 77:4911-4927.
29. Angelosnato J.M., Blackburn S.D., Crawford A., Wherry E.J. Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection. J Virol 2012, 86:8161-8170.
30. Luzina I.G., Pickering E.M., Kopach P., et al. Full-length IL-33 promotes inflammation but not Th2 response in vivo in an ST2-independent fashion. J Immunol 2012, 189(1):403-410.
31. Kuroswska-stolarska M., Hueber A., Stolarski B., McInnes I.B. Interleukin-33: a novel mediator with a role in distinct disease pathologies. J Intern Med 2011, 269(1):29-35.
32. Hansen S.G., Vieville C., Whizin N., et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009, 15:293-299.
33. Hansen S.G., Ford J.C., Lewis M.S., et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473:523-527.
34. Van Duikeren S., Fransen M.F., Redeker A., et al. Vaccine-induced effector memory CD8 T cell responses predict therapeutic efficacy against tumors. J Immunol 2012, 189(7):3397-3403.